Lupin reports strong Q2 FY26 performance with significant growth

Lupin Limited's board of directors unanimously approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Consolidated net sales for Q2 FY26 increased by 24.3% year-over-year to INR 68,314 million, with a net income of INR 14,779 million, up 73.3%. For the half-year ended September 30, 2025, consolidated net sales were INR 129,952 million, an 18.0% increase, and net income grew by 63.1% to INR 26,970 million.

The company witnessed strong growth across various markets, with U.S. sales up 47.3% to INR 27,624 million in Q2 FY26. India sales also increased by 3.4% to INR 20,777 million, maintaining Lupin’s position as the 8th largest company in the Indian Pharmaceutical Market. Investment in R&D for the quarter was INR 5,091 million.

Operational highlights include receiving 6 ANDA approvals from the U.S. FDA, with cumulative filings reaching 433 and 341 approvals to date. Lupin also strengthened its global specialty ophthalmology business and expanded its strategic partnership for the PrecisionSphere™ platform. The company's ESG efforts were recognized with an S&P Global ESG Rating of 91/100 and an MSCI ESG Rating upgrade to BBB in 2025.